Please try another search
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Name | Age | Since | Title |
---|---|---|---|
Julie H. McHugh | 57 | 2014 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review